<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Perrigo Company</title>
	<atom:link href="http://www.stockbloghub.com/tag/perrigo-co/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SGP) Schering-Plough Settles Lawsuits &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445</link>
		<comments>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445#comments</comments>
		<pubDate>Thu, 13 Aug 2009 00:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Caraco Pharmaceutical Laborato]]></category>
		<category><![CDATA[CPD]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[GeoPharma Inc.]]></category>
		<category><![CDATA[GORX]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12445</guid>
		<description><![CDATA[Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals &#38; Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex. This signals the end of all pending litigations that Schering filed against several generic drug manufacturing companies in the US District Court of New Jersey since 2006. These companies wanted to market solid oral doses of the drug, desloratadine, in the U.S. as generic brands before the expiration of certain Schering patents. Pursuant to the agreement, Orchid received rights to launch a generic version of the Clarinex brand Reditabs in the U.S. on Jan. 1, 2012 and Clarinex brand 5 milligram tablets on July 1 of that year. Schering holds various patents related to Clarinex till 2022. Schering has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Company &#8211; ROE of 17% &#8211; more than the double the industry average of 8%</title>
		<link>http://www.stockbloghub.com/2009/01/14/prgo-perrigo-company-roe-of-17-more-than-the-double-the-industry-average-of-8/2106</link>
		<comments>http://www.stockbloghub.com/2009/01/14/prgo-perrigo-company-roe-of-17-more-than-the-double-the-industry-average-of-8/2106#comments</comments>
		<pubDate>Thu, 15 Jan 2009 01:47:15 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2106</guid>
		<description><![CDATA[Perrigo Co. (PRGO) has a return on equity (ROE) of 17%, more than the double the industry’s average of 8%. The company’s earnings per share are expected to grow by 21% over the next 3 – 5 years, while the industry average expectation stands at 15%. Company Description Perrigo is the nation&#8217;s largest manufacturer of store brand over-the-counter (non-prescription) pharmaceutical products and it manufactures store brand nutritional products. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company&#8217;s products include analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and vitamins, nutritional supplements and nutritional drinks. Recent Events The company recently announced that it received final approval from the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/14/prgo-perrigo-company-roe-of-17-more-than-the-double-the-industry-average-of-8/2106/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

